Skip to content

Cariprazine hydrochloride

Vraylar, Reagila (cariprazine hydrochloride) is a small molecule pharmaceutical. Cariprazine hydrochloride was first approved as Vraylar on 2017-07-13. It is used to treat in the USA. It has been approved in Europe to treat schizopyrenida. Vraylar's patents are valid until 2029-09-17 (FDA).
Trade Name Reagila
Common Name Cariprazine hydrochloride
Indication schizopyrenida
Drug Class
Cariprazine hydrochloride
Get full access now